Aethlon Medical Inc (NAS:AEMD)

Q3 2026 Aethlon Medical Inc Earnings Call Transcript

Feb 12, 2026 / 09:30 PM GMT

Release Date Price: $9.9 (-5.26%)

Transcript 10-Q8-K

Key Points

Positve

Aethlon Medical Inc (AEMD) reported progress in their Australian oncology trial, with successful completion of the first cohort and ongoing treatments in the second cohort.
The company is expanding its extracellular vesicle (EV) research platform, supporting the hemopurifier as a potential multi-indication therapeutic.
Aethlon Medical Inc (AEMD) is advancing work on hemopurifier compatibility with a simplified blood treatment system, which could expand clinical and commercial flexibility.
The company has achieved sustained operating expense reductions on a year-to-date basis compared to the prior year.
Aethlon Medical Inc (AEMD) has a cash balance of approximately $7 million as of December 31, 2025, indicating a stable financial position.

Negative

Consolidated operating expenses for the quarter increased by 13.6% compared to the same period last year, primarily due to higher payroll and related costs.
The operating loss for the quarter increased to $2.06 million compared to $1.81 million in the prior year period.
Interest income earned on cash balances was lower than the previous year, at $44,000 compared to $60,000.
The company is still in the early stages of its oncology trial, with the third cohort yet to be initiated, indicating that significant progress is still needed.
There are potential regulatory hurdles and compatibility tests required for the integration of the hemopurifier with the new SLAMB SAA system, which could delay future developments.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AEMD.OQ - Aethlon Medical Inc
Q3 2026 Aethlon Medical Inc Earnings Call
Feb 12, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Athlon Medical 3rd quarter fiscal 2026 earnings and corporate update conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press, then 1 on a touchtone phone. To withdraw your question, please press 2. Please note that this event is being recorded. I would now like to turn the conference over to CEO and CFO Jim Frakes. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.